Asia
With COVID-19 still running rampant across the globe, Moderna announced it will rapidly expand its vaccine manufacturing operations in order to meet demand in the countries where the medication has received emergency authorization.
Researchers with Shenzhen Institutes of Advanced Technology in China used a variety of computational techniques to simulate drug-virus interactions. They then screened 1,906 existing drugs to evaluate which ones might inhibit replication of SARS-CoV-2, the virus that causes COVID-19.
Sinopharm, a Chinese biopharmaceutical company controlled by the state, announced that its COVID-19 vaccine candidate had an efficacy rate of 79% based on interim analysis of Phase III trials.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The United Kingdom is expected to give the green light to the vaccine developed by AstraZeneca and Oxford University this week.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Even with the holidays among us, there were a number of clinical trial announcements. Here’s a look.
A phase 3 study from Daiichi Sankyo Company conducted in Japan, South Korea and Taiwan found that mirogabalin, an orally administered gabapentinoid, was associated with a significantly greater improvement in pain among patients with central neuropathic pain after spinal cord injury compared with placebo.
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
On Wednesday, Sage Therapeutics and Samsung Biologics announced that they had found just that in their new chief executive officers.
PRESS RELEASES